Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 GBX | -11.69% | +7.94% | +61.90% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+61.90% | 21.32M | - | ||
-3.58% | 12.64B | B+ | ||
-1.48% | 8.46B | B- | ||
+8.70% | 5.66B | B | ||
+25.61% | 5.27B | C | ||
-4.58% | 4.49B | C | ||
-51.80% | 3.11B | D+ | ||
+16.25% | 2.87B | - | - | |
+30.25% | 2.31B | C | ||
-4.08% | 1.89B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GENI Stock
- Ratings GENinCode Plc